SEARCH

SEARCH BY CITATION

References

  • Ansell, S.M., Inwards, D.J., Rowland, Jr, K.M., Flynn, P.J., Morton, R.F., Moore, Jr, D.F., Kaufmann, S.H., Ghobrial, I., Kurtin, P.J., Maurer, M., Allmer, C. & Witzig, T.E. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer, 113, 508514.
  • Asnaghi, L., Calastretti, A., Bevilacqua, A., D’Agnano, I., Gatti, G., Canti, G., Delia, D., Capaccioli, S. & Nicolin, A. (2004) Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene, 23, 57817594.
  • Avellino, R., Romano, S., Parasole, R., Bisogni, R., Lamberti, A., Poggi, V., Venuta, S. & Romano, M.F. (2005) Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood, 106, 14001406.
  • Baldo, P., Cecco, S., Giacomin, E., Lazzarini, R., Ros, B. & Marastoni, S. (2008) mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets, 8, 647665.
  • Bhaskar, P.T. & Hay, N. (2007) The two TORCs and Akt. Developmental Cell, 12, 487502.
  • Bleesing, J.J., Straus, S.E. & Fleisher, T.A. (2000) Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatric Clinics of North America, 47, 12911310.
  • Boratynska, M. & Smolska, D. (2008) Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transplant International, 21, 605608.
  • Breslin, E.M., White, P.C., Shore, A.M., Clement, M. & Brennan, P. (2005) LY294002 and rapamycin co-operate to inhibit T-cell proliferation. British Journal of Pharmacology, 144, 791800.
  • Brown, V.I., Fang, J., Alcorn, K., Barr, R., Kim, J.M., Wasserman, R. & Grupp, S.A. (2003) Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proceedings of the National Academy of Sciences of the United States of America, 100, 1511315118.
  • Brown, V.I., Hulitt, J., Fish, J., Sheen, C., Bruno, M., Xu, Q., Carroll, M., Fang, J., Teachey, D. & Grupp, S.A. (2007) Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Research, 67, 99639970.
  • Brown, V.I., Seif, A.E., Reid, G.S., Teachey, D.T. & Grupp, S.A. (2008) Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research, 42, 84105.
  • Brusko, T.M., Putnam, A.L. & Bluestone, J.A. (2008) Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunological Reviews, 223, 371390.
  • Bruyn, G.A., Tate, G., Caeiro, F., Maldonado-Cocco, J., Westhovens, R., Tannenbaum, H., Bell, M., Forre, O., Bjorneboe, O., Tak, P.P., Abeywickrama, K.H., Bernhardt, P. & Van Riel, P.L. (2008) Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the Rheumatic Diseases, 67, 10901095.
  • Calastretti, A., Rancati, F., Ceriani, M.C., Asnaghi, L., Canti, G. & Nicolin, A. (2001) Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. European Journal of Cancer, 37, 21212128.
  • Chumsri, S., Zhao, M., Garofalo, M., Burger, A., Hamburger, A., Zhao, F. & Rapoport, A. (2008) Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leukaemia & Lymphoma, 49, 359361.
  • Crazzolara, R., Cisterne, A., Thien, M., Hewson, J., Bradstock, K. & Bendall, L. (2007) The mTOR inhibitor RAD001 (Everolimus) improves survival in preclinical models of primary human ALL. Blood (ASH Annual Meeting Abstracts), 110, 856.
  • Decker, T., Hipp, S., Ringshausen, I., Bogner, C., Oelsner, M., Schneller, F. & Peschel, C. (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood, 101, 278285.
  • Decker, T., Sandherr, M., Goetze, K., Oelsner, M., Ringshausen, I. & Peschel, C. (2008) A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Annals of Hematology, 88, 221227.
  • Dighiero, G. & Hamblin, T.J. (2008) Chronic lymphocytic leukaemia. Lancet, 371, 10171029.
  • Dunn, C. & Croom, K.F. (2006) Everolimus: a review of its use in renal and cardiac transplantation. Drugs, 66, 547570.
  • Dutton, A., Reynolds, G.M., Dawson, C.W., Young, L.S. & Murray, P.G. (2005) Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. Journal of Pathology, 205, 498506.
  • El-Salem, M., Raghunath, P.N., Marzec, M., Wlodarski, P., Tsai, D., Hsi, E. & Wasik, M.A. (2007) Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Laboratory Investigation, 87, 2939.
  • Ewen, M.E., Sluss, H.K., Sherr, C.J., Matsushime, H., Kato, J. & Livingston, D.M. (1993) Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73, 487497.
  • Faivre, S., Kroemer, G. & Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nature reviews. Drug discovery, 5, 671688.
  • Follo, M.Y., Mongiorgi, S., Bosi, C., Cappellini, A., Finelli, C., Chiarini, F., Papa, V., Libra, M., Martinelli, G., Cocco, L. & Martelli, A.M. (2007) The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Research, 67, 42874294.
  • Francis, L.K., Alsayed, Y., Leleu, X., Jia, X., Singha, U.K., Anderson, J., Timm, M., Ngo, H., Lu, G., Huston, A., Ehrlich, L.A., Dimmock, E., Lentzsch, S., Hideshima, T., Roodman, G.D., Anderson, K.C. & Ghobrial, I.M. (2006) Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clinical Cancer Research, 12, 68266835.
  • Frost, P., Moatamed, F., Hoang, B., Shi, Y., Gera, J., Yan, H., Gibbons, J. & Lichtenstein, A. (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood, 104, 41814187.
  • Gera, J.F., Mellinghoff, I.K., Shi, Y., Rettig, M.B., Tran, C., Hsu, J.H., Sawyers, C.L. & Lichtenstein, A.K. (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. Journal of Biological Chemistry, 279, 27372746.
  • Gora-Tybor, J. & Robak, T. (2008) Targeted drugs in chronic myeloid leukemia. Current Medicinal Chemistry, 15, 30363051.
  • Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 20792088.
  • Gu, L., Gao, J., Li, Q., Zhu, Y.P., Jia, C.S., Fu, R.Y., Chen, Y., Liao, Q.K. & Ma, Z. (2008) Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia, 22, 20912096.
  • Haarman, E.G., Kaspers, G.J., Pieters, R., Rottier, M.M. & Veerman, A.J. (2008) Circumvention of glucocorticoid resistance in childhood leukemia. Leukemia Research, 32, 14171423.
  • Haritunians, T., Mori, A., O’Kelly, J., Luong, Q.T., Giles, F.J. & Koeffler, H.P. (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 21, 333339.
  • Harrington, L.S., Findlay, G.M. & Lamb, R.F. (2005) Restraining PI3K: mTOR signalling goes back to the membrane. Trends in Biochemical Sciences, 30, 3542.
  • Hartmann, E.M., Ott, G. & Rosenwald, A. (2008) Molecular biology and genetics of lymphomas. Hematology/Oncology Clinics of North America, 22, 807823.
  • Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N.C., Chauhan, D., Richardson, P.G. & Anderson, K.C. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 40534062.
  • Hipp, S., Ringshausen, I., Oelsner, M., Bogner, C., Peschel, C. & Decker, T. (2005) Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica, 90, 14331434.
  • Hirase, C., Maeda, Y., Takai, S. & Kanamaru, A. (2008) Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leukemia Research, 33, 450459.
  • Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A. & Smith, M.A. (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer, 50, 799805.
  • Huang, S., Bjornsti, M.A. & Houghton, P.J. (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biology & Therapy, 2, 222232.
  • Ikezoe, T., Nishioka, C., Tasaka, T., Yang, Y., Komatsu, N., Togitani, K., Koeffler, H.P. & Taguchi, H. (2006) The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Molecular Cancer Therapeutics, 5, 25222530.
  • Inoki, K., Corradetti, M.N. & Guan, K.L. (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nature Genetics, 37, 1924.
  • Jundt, F., Raetzel, N., Muller, C., Calkhoven, C.F., Kley, K., Mathas, S., Lietz, A., Leutz, A. & Dorken, B. (2005) A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 106, 18011807.
  • Kharas, M.G., Deane, J.A., Wong, S., O’Bosky, K.R., Rosenberg, N., Witte, O.N. & Fruman, D.A. (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood, 103, 42684275.
  • Kharas, M.G., Janes, M.R., Scarfone, V.M., Lilly, M.B., Knight, Z.A., Shokat, K.M. & Fruman, D.A. (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. Journal of Clinical Investigation, 118, 30383050.
  • Kim, J.H., Chu, S.C., Gramlich, J.L., Pride, Y.B., Babendreier, E., Chauhan, D., Salgia, R., Podar, K., Griffin, J.D. & Sattler, M. (2005) Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood, 105, 17171723.
  • Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 29622972.
  • Leseux, L., Laurent, G., Laurent, C., Rigo, M., Blanc, A., Olive, D. & Bezombes, C. (2008) PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood, 111, 285291.
  • Levy, D.S., Kahana, J.A. & Kumar, R. (2008) AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood, 113, 17231729.
  • Lewin, K.J. (1997) Post-transplant lymphoproliferative disorders. Pathology Oncology Research, 3, 177182.
  • Liem, N.L., Papa, R.A., Milross, C.G., Schmid, M.A., Tajbakhsh, M., Choi, S., Ramirez, C.D., Rice, A.M., Haber, M., Norris, M.D., MacKenzie, K.L. & Lock, R.B. (2004) Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood, 103, 39053914.
  • Lin, T.S. (2008) Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clinical Lymphoma Myeloma, 8(Suppl. 4), S137S143.
  • Luger, S., Perl, A.E., Kemner, A., Stadtmauer, E., Porter, D., Schuster, S.J., Goldstein, S., Tsai, D., Loren, N., Dierov, J., Vogl, D., Andreadis, C., Emerson, S.G. & Carroll, M. (2006) A phase 1 dose escalation study of the mTOR inhibitor sirolimus and MEC chemotherapy targeting signal transduction in leukemic stem cells for acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 108, 161.
  • Ly, C., Arechiga, A.F., Melo, J.V., Walsh, C.M. & Ong, S.T. (2003) Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Research, 63, 57165722.
  • Majewski, M., Korecka, M., Joergensen, J., Fields, L., Kossev, P., Schuler, W., Shaw, L. & Wasik, M.A. (2003) Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation, 75, 17101717.
  • Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M., Manola, J., Brugarolas, J., McDonnell, T.J., Golub, T.R., Loda, M., Lane, H.A. & Sellers, W.R. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594601.
  • Mayerhofer, M., Aichberger, K.J., Florian, S., Krauth, M.T., Hauswirth, A.W., Derdak, S., Sperr, W.R., Esterbauer, H., Wagner, O., Marosi, C., Pickl, W.F., Deininger, M., Weisberg, E., Druker, B.J., Griffin, J.D., Sillaber, C. & Valent, P. (2005) Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB Journal, 19, 960962.
  • Mills, G.B., Lu, Y. & Kohn, E.C. (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 1003110033.
  • Mohi, M.G., Boulton, C., Gu, T.L., Sternberg, D.W., Neuberg, D., Griffin, J.D., Gilliland, D.G. & Neel, B.G. (2004) Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proceedings of the National Academy of Sciences of the United States of America, 101, 31303135.
  • Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H. & Sawyers, C.L. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America, 98, 1031410319.
  • Nishioka, C., Ikezoe, T., Yang, J., Koeffler, H.P. & Yokoyama, A. (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia, 22, 21592168.
  • Papa, V., Tazzari, P.L., Chiarini, F., Cappellini, A., Ricci, F., Billi, A.M., Evangelisti, C., Ottaviani, E., Martinelli, G., Testoni, N., McCubrey, J.A. & Martelli, A.M. (2008) Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 22, 147160.
  • Park, S., Chapuis, N., Bardet, V., Tamburini, J., Gallay, N., Willems, L., Knight, Z.A., Shokat, K.M., Azar, N., Viguie, F., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C. & Bouscary, D. (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 22, 16981706.
  • Pascual, J. (2007) Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrology, Dialysis, Transplantation, 22(Suppl. 1), i27i35.
  • Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. & Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 65876597.
  • Peponi, E., Drakos, E., Reyes, G., Leventaki, V., Rassidakis, G.Z. & Medeiros, L.J. (2006) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. American Journal of Pathology, 169, 21712180.
  • Perl, A.E. & Carroll, M. (2007) Exploiting signal transduction pathways in acute myelogenous leukemia. Current treatment options in oncology, 8, 265276.
  • Piccaluga, P.P., Paolini, S. & Martinelli, G. (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer, 110, 11781186.
  • Plasschaert, S.L., Kamps, W.A., Vellenga, E., De Vries, E.G. & De Bont, E.S. (2004) Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treatment Reviews, 30, 3751.
  • Pulsipher, M., Wall, D., Goyal, R., Grupp, S.A. & Bunin, N. (2008) Sirolimus (SRL)-Based GVHD Prophylaxis after TBI/TT/Cy Allogeneic HSCT in Pediatric Patients with HR ALL: Results of a Multi-Insitutional Pilot Study. O Biologico Blood Marrow Transplant 2008 ASBMT Annual Meeting Abstracts, 14, 28.
  • Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N.C., Stirling, D.I., Antin, J.H. & Anderson, K.C. (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 104, 41884193.
  • Ramos-Barron, A., Pinera-Haces, C., Gomez-Alamillo, C., Santiuste-Torcida, I., Ruiz, J.C., Buelta-Carrillo, L., Merino, R., De Francisco, A.L. & Arias, M. (2007) Prevention of murine lupus disease in (NZBxNZW) F1 mice by sirolimus treatment. Lupus, 16, 775781.
  • Recher, C., Dos Santos, C., Demur, C. & Payrastre, B. (2005) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle, 4, 15401549.
  • Rheingold, S., Sacks, N., Chang, Y.J., Brown, V.I., Teachey, D.T., Lange, B. & Grupp, S.A. (2007) A phase I trial of sirolimus (rapamycin) in pediatric patients with relapsed/refractory leukemia. Blood (ASH Annual Meeting Abstracts), 110, 2834.
  • Ringshausen, I., Schneller, F., Bogner, C., Hipp, S., Duyster, J., Peschel, C. & Decker, T. (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood, 100, 37413748.
  • Ringshausen, I., Peschel, C. & Decker, T. (2005) Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leukaemia & Lymphoma, 46, 1119.
  • Rizzieri, D.A., Feldman, E., Dipersio, J.F., Gabrail, N., Stock, W., Strair, R., Rivera, V.M., Albitar, M., Bedrosian, C.L. & Giles, F.J. (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 14, 27562762.
  • Rosner, M. & Hengstschlager, M. (2008) Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Human Molecular Genetics, 17, 29342948.
  • Rudelius, M., Pittaluga, S., Nishizuka, S., Pham, T.H., Fend, F., Jaffe, E.S., Quintanilla-Martinez, L. & Raffeld, M. (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 108, 16681676.
  • Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Naoe, T., Lengfelder, E., Buchner, T., Dohner, H., Burnett, A.K. & Lo-Coco, F. (2009) Guidelines on the management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 113, 18751891.
  • Saydam, G., H, C., P, C., Bertino, J.R. & Erickan-Abali, E. (2005) mTOR inhibition leads to increased sensitivity to methotrexate. AACR 98th Annual Meeting. Abstract No. 3303 .
  • Schmelzle, T. & Hall, M.N. (2000) TOR, a central controller of cell growth. Cell, 103, 253262.
  • Schmidt, C. & Dreyling, M. (2008) Therapy of mantle cell lymphoma: current standards and future strategies. Hematology/Oncology Clinics of North America, 22, 953963.
  • Shaw, R.J. & Cantley, L.C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424430.
  • Shi, Y., Gera, J., Hu, L., Hsu, J.H., Bookstein, R., Li, W. & Lichtenstein, A. (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Research, 62, 50275034.
  • Sillaber, C., Mayerhofer, M., Bohm, A., Vales, A., Gruze, A., Aichberger, K.J., Esterbauer, H., Pfeilstocker, M., Sperr, W.R., Pickl, W.F., Haas, O.A. & Valent, P. (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. European Journal of Clinical Investigation, 38, 4352.
  • Smith, M.S., Pro, B., Cisneros, A., Smith, S., Stiff, P., Lester, E., Modi, S., Dancey, J.E., Vokes, E.E. & Van Besian, K.(2008) Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. Journal of Clinical Oncology ( ASCO Annual Meeting ), 26(Suppl.), 8514.
  • Teachey, D.T., Obzut, D.A., Cooperman, J., Fang, J., Carroll, M., Choi, J.K., Houghton, P.J., Brown, V.I. & Grupp, S.A. (2006a) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 107, 11491155.
  • Teachey, D.T., Obzut, D.A., Axsom, K., Choi, J.K., Goldsmith, K.C., Hall, J., Hulitt, J., Manno, C.S., Maris, J.M., Rhodin, N., Sullivan, K.E., Brown, V.I. & Grupp, S.A. (2006b) Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood, 108, 19651971.
  • Teachey, D.T., Sheen, C., Hall, J., Ryan, T., Brown, V.I., Fish, J., Reid, G.S., Seif, A.E., Norris, R., Chang, Y.J., Carroll, M. & Grupp, S.A. (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood, 112, 20202023.
  • Teachey, D.T., Greiner, R., Seif, A.E., Attiyeh, E.F., Bleesing, J.J., Choi, J.K., Manno, C.S., Rappaport, E., Schwabe, D., Sheen, C., Sullivan, K.E., Zhaung, H., Wechsler, D.S. & Grupp, S.A. (2009) Treatment with sirolimus results in complete responses in patients with Autoimmune Lymphoproliferative Syndrome. British Journal of Haematology, 145, 101106.
  • Tisdale, J.F., Dunn, D.E. & Maciejewski, J. (2000) Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. Seminars in Hematology, 37, 102109.
  • Vega, F., Medeiros, L.J., Leventaki, V., Atwell, C., Cho-Vega, J.H., Tian, L., Claret, F.X. & Rassidakis, G.Z. (2006) Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Research, 66, 65896597.
  • Wanner, K., Hipp, S., Oelsner, M., Ringshausen, I., Bogner, C., Peschel, C. & Decker, T. (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. British Journal of Haematology, 134, 475484.
  • Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R.W., Opferman, J.T., Sallan, S.E., Den Boer, M.L., Pieters, R., Golub, T.R. & Armstrong, S.A. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 10, 331342.
  • Wullschleger, S., Loewith, R. & Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell, 124, 471484.
  • Xu, Q., Simpson, S.E., Scialla, T.J., Bagg, A. & Carroll, M. (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 102, 972980.
  • Xu, Q., Thompson, J.E. & Carroll, M. (2005a) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood, 106, 42614268.
  • Xu, R.H., Pelicano, H., Zhang, H., Giles, F.J., Keating, M.J. & Huang, P. (2005b) Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia, 19, 21532158.
  • Yan, H., Frost, P., Shi, Y., Hoang, B., Sharma, S., Fisher, M., Gera, J. & Lichtenstein, A. (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Research, 66, 23052313.
  • Yango, A., Morrissey, P., Monaco, A., Butera, J. & Gohh, R.Y. (2002) Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clinical Nephrology, 58, 7778.
  • Yee, K.W., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., O’Brien, S., Andreeff, M. & Giles, F.J. (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 12, 51655173.
  • Younes, A. (2008) Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers. Autophagy, 4, 707709.
  • Zanesi, N., Aqeilan, R., Drusco, A., Kaou, M., Sevignani, C., Costinean, S., Bortesi, L., La Rocca, G., Koldovsky, P., Volinia, S., Mancini, R., Calin, G., Scott, C.P., Pekarsky, Y. & Croce, C.M. (2006) Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Research, 66, 915920.
  • Zeng, X. & Kinsella, T.J. (2008) Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Research, 68, 23842390.